Kymera Therapeutics Inc (KYMR)
32.11
-0.05
(-0.16%)
USD |
NASDAQ |
May 31, 16:00
32.10
-0.02
(-0.05%)
After-Hours: 20:00
Kymera Therapeutics Enterprise Value: 1.450B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 1.450B |
| May 30, 2024 | 1.453B |
| May 29, 2024 | 1.473B |
| May 28, 2024 | 1.537B |
| May 24, 2024 | 1.569B |
| May 23, 2024 | 1.580B |
| May 22, 2024 | 1.670B |
| May 21, 2024 | 1.647B |
| May 20, 2024 | 1.689B |
| May 17, 2024 | 1.624B |
| May 16, 2024 | 1.664B |
| May 15, 2024 | 1.685B |
| May 14, 2024 | 1.633B |
| May 13, 2024 | 1.833B |
| May 10, 2024 | 1.805B |
| May 09, 2024 | 1.848B |
| May 08, 2024 | 1.842B |
| May 07, 2024 | 1.838B |
| May 06, 2024 | 1.829B |
| May 03, 2024 | 1.774B |
| May 02, 2024 | 1.707B |
| May 01, 2024 | 1.703B |
| April 30, 2024 | 1.542B |
| April 29, 2024 | 1.606B |
| April 26, 2024 | 1.527B |
| Date | Value |
|---|---|
| April 25, 2024 | 1.526B |
| April 24, 2024 | 1.640B |
| April 23, 2024 | 1.671B |
| April 22, 2024 | 1.587B |
| April 19, 2024 | 1.564B |
| April 18, 2024 | 1.634B |
| April 17, 2024 | 1.551B |
| April 16, 2024 | 1.561B |
| April 15, 2024 | 1.589B |
| April 12, 2024 | 1.662B |
| April 11, 2024 | 1.762B |
| April 10, 2024 | 1.647B |
| April 09, 2024 | 1.787B |
| April 08, 2024 | 1.711B |
| April 05, 2024 | 1.713B |
| April 04, 2024 | 1.703B |
| April 03, 2024 | 1.757B |
| April 02, 2024 | 1.789B |
| April 01, 2024 | 1.898B |
| March 31, 2024 | 1.946B |
| March 28, 2024 | 2.082B |
| March 27, 2024 | 2.080B |
| March 26, 2024 | 2.038B |
| March 25, 2024 | 2.039B |
| March 22, 2024 | 2.114B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
250.87M
Minimum
Oct 27 2023
3.611B
Maximum
Dec 28 2020
1.507B
Average
1.411B
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group Inc | 63.02M |
| Iovance Biotherapeutics Inc | 2.130B |
| Immunic Inc | 15.29M |
| Protagonist Therapeutics Inc | 1.328B |
| Ovid Therapeutics Inc | 127.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.56M |
| Revenue (Quarterly) | 10.29M |
| Total Expenses (Quarterly) | 63.19M |
| EPS Diluted (Quarterly) | -0.69 |
| Profit Margin (Quarterly) | -472.0% |
| Earnings Yield | -7.82% |
| Normalized Earnings Yield | -7.600 |